Tag Archives: inventors
#437974 China Wants to Be the World’s AI ...
China’s star has been steadily rising for decades. Besides slashing extreme poverty rates from 88 percent to under 2 percent in just 30 years, the country has become a global powerhouse in manufacturing and technology. Its pace of growth may slow due to an aging population, but China is nonetheless one of the world’s biggest players in multiple cutting-edge tech fields.
One of these fields, and perhaps the most significant, is artificial intelligence. The Chinese government announced a plan in 2017 to become the world leader in AI by 2030, and has since poured billions of dollars into AI projects and research across academia, government, and private industry. The government’s venture capital fund is investing over $30 billion in AI; the northeastern city of Tianjin budgeted $16 billion for advancing AI; and a $2 billion AI research park is being built in Beijing.
On top of these huge investments, the government and private companies in China have access to an unprecedented quantity of data, on everything from citizens’ health to their smartphone use. WeChat, a multi-functional app where people can chat, date, send payments, hail rides, read news, and more, gives the CCP full access to user data upon request; as one BBC journalist put it, WeChat “was ahead of the game on the global stage and it has found its way into all corners of people’s existence. It could deliver to the Communist Party a life map of pretty much everybody in this country, citizens and foreigners alike.” And that’s just one (albeit big) source of data.
Many believe these factors are giving China a serious leg up in AI development, even providing enough of a boost that its progress will surpass that of the US.
But there’s more to AI than data, and there’s more to progress than investing billions of dollars. Analyzing China’s potential to become a world leader in AI—or in any technology that requires consistent innovation—from multiple angles provides a more nuanced picture of its strengths and limitations. In a June 2020 article in Foreign Affairs, Oxford fellows Carl Benedikt Frey and Michael Osborne argued that China’s big advantages may not actually be that advantageous in the long run—and its limitations may be very limiting.
Moving the AI Needle
To get an idea of who’s likely to take the lead in AI, it could help to first consider how the technology will advance beyond its current state.
To put it plainly, AI is somewhat stuck at the moment. Algorithms and neural networks continue to achieve new and impressive feats—like DeepMind’s AlphaFold accurately predicting protein structures or OpenAI’s GPT-3 writing convincing articles based on short prompts—but for the most part these systems’ capabilities are still defined as narrow intelligence: completing a specific task for which the system was painstakingly trained on loads of data.
(It’s worth noting here that some have speculated OpenAI’s GPT-3 may be an exception, the first example of machine intelligence that, while not “general,” has surpassed the definition of “narrow”; the algorithm was trained to write text, but ended up being able to translate between languages, write code, autocomplete images, do math, and perform other language-related tasks it wasn’t specifically trained for. However, all of GPT-3’s capabilities are limited to skills it learned in the language domain, whether spoken, written, or programming language).
Both AlphaFold’s and GPT-3’s success was due largely to the massive datasets they were trained on; no revolutionary new training methods or architectures were involved. If all it was going to take to advance AI was a continuation or scaling-up of this paradigm—more input data yields increased capability—China could well have an advantage.
But one of the biggest hurdles AI needs to clear to advance in leaps and bounds rather than baby steps is precisely this reliance on extensive, task-specific data. Other significant challenges include the technology’s fast approach to the limits of current computing power and its immense energy consumption.
Thus, while China’s trove of data may give it an advantage now, it may not be much of a long-term foothold on the climb to AI dominance. It’s useful for building products that incorporate or rely on today’s AI, but not for pushing the needle on how artificially intelligent systems learn. WeChat data on users’ spending habits, for example, would be valuable in building an AI that helps people save money or suggests items they might want to purchase. It will enable (and already has enabled) highly tailored products that will earn their creators and the companies that use them a lot of money.
But data quantity isn’t what’s going to advance AI. As Frey and Osborne put it, “Data efficiency is the holy grail of further progress in artificial intelligence.”
To that end, research teams in academia and private industry are working on ways to make AI less data-hungry. New training methods like one-shot learning and less-than-one-shot learning have begun to emerge, along with myriad efforts to make AI that learns more like the human brain.
While not insignificant, these advancements still fall into the “baby steps” category. No one knows how AI is going to progress beyond these small steps—and that uncertainty, in Frey and Osborne’s opinion, is a major speed bump on China’s fast-track to AI dominance.
How Innovation Happens
A lot of great inventions have happened by accident, and some of the world’s most successful companies started in garages, dorm rooms, or similarly low-budget, nondescript circumstances (including Google, Facebook, Amazon, and Apple, to name a few). Innovation, the authors point out, often happens “through serendipity and recombination, as inventors and entrepreneurs interact and exchange ideas.”
Frey and Osborne argue that although China has great reserves of talent and a history of building on technologies conceived elsewhere, it doesn’t yet have a glowing track record in terms of innovation. They note that of the 100 most-cited patents from 2003 to present, none came from China. Giants Tencent, Alibaba, and Baidu are all wildly successful in the Chinese market, but they’re rooted in technologies or business models that came out of the US and were tweaked for the Chinese population.
“The most innovative societies have always been those that allowed people to pursue controversial ideas,” Frey and Osborne write. China’s heavy censorship of the internet and surveillance of citizens don’t quite encourage the pursuit of controversial ideas. The country’s social credit system rewards people who follow the rules and punishes those who step out of line. Frey adds that top-down execution of problem-solving is effective when the problem at hand is clearly defined—and the next big leaps in AI are not.
It’s debatable how strongly a culture of social conformism can impact technological innovation, and of course there can be exceptions. But a relevant historical example is the Soviet Union, which, despite heavy investment in science and technology that briefly rivaled the US in fields like nuclear energy and space exploration, ended up lagging far behind primarily due to political and cultural factors.
Similarly, China’s focus on computer science in its education system could give it an edge—but, as Frey told me in an email, “The best students are not necessarily the best researchers. Being a good researcher also requires coming up with new ideas.”
Winner Take All?
Beyond the question of whether China will achieve AI dominance is the issue of how it will use the powerful technology. Several of the ways China has already implemented AI could be considered morally questionable, from facial recognition systems used aggressively against ethnic minorities to smart glasses for policemen that can pull up information about whoever the wearer looks at.
This isn’t to say the US would use AI for purely ethical purposes. The military’s Project Maven, for example, used artificially intelligent algorithms to identify insurgent targets in Iraq and Syria, and American law enforcement agencies are also using (mostly unregulated) facial recognition systems.
It’s conceivable that “dominance” in AI won’t go to one country; each nation could meet milestones in different ways, or meet different milestones. Researchers from both countries, at least in the academic sphere, could (and likely will) continue to collaborate and share their work, as they’ve done on many projects to date.
If one country does take the lead, it will certainly see some major advantages as a result. Brookings Institute fellow Indermit Gill goes so far as to say that whoever leads in AI in 2030 will “rule the world” until 2100. But Gill points out that in addition to considering each country’s strengths, we should consider how willing they are to improve upon their weaknesses.
While China leads in investment and the US in innovation, both nations are grappling with huge economic inequalities that could negatively impact technological uptake. “Attitudes toward the social change that accompanies new technologies matter as much as the technologies, pointing to the need for complementary policies that shape the economy and society,” Gill writes.
Will China’s leadership be willing to relax its grip to foster innovation? Will the US business environment be enough to compete with China’s data, investment, and education advantages? And can both countries find a way to distribute technology’s economic benefits more equitably?
Time will tell, but it seems we’ve got our work cut out for us—and China does too.
Image Credit: Adam Birkett on Unsplash Continue reading
Posted in Human Robots
#437673 Can AI and Automation Deliver a COVID-19 ...
Illustration: Marysia Machulska
Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.
“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.
In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.
Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.
There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”
That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.
“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”
There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.
Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, antivirals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.
The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.
But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.
Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.
And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.
While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”
Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.
Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.
Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.
And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.
To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”
Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.
1/5
STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot
2/5
STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.
3/5
STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.
4/5
STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.
5/5
STEP 5: The most promising compounds are tested against live virus samples.
Previous
Next
Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.
For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.
The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.
Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.
That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.
First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.
Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.
Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.
Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s AI-generated molecules in virtual reality.
Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.
Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.
Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.
Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.
The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.
Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.
Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.
While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.
In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.
“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.
While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.
“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”
This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading
Posted in Human Robots
#437643 Video Friday: Matternet Launches Urban ...
Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):
IROS 2020 – October 25-25, 2020 – [Online]
Bay Area Robotics Symposium – November 20, 2020 – [Online]
ACRA 2020 – December 8-10, 2020 – [Online]
Let us know if you have suggestions for next week, and enjoy today's videos.
Sixteen teams chose their roster of virtual robots and sensor payloads, some based on real-life subterranean robots, and submitted autonomy and mapping algorithms that SubT Challenge officials then tested across eight cave courses in the cloud-based SubT Simulator. Their robots traversed the cave environments autonomously, without any input or adjustments from human operators. The Cave Circuit Virtual Competition teams earned points by correctly finding, identifying, and localizing up to 20 artifacts hidden in the cave courses within five-meter accuracy.
[ SubT ]
This year, the KUKA Innovation Award’s international jury of experts received a total of more than 40 ideas. The five finalist teams had time until November to implement their ideas. A KUKA LBR Med lightweight robot – the first robotic component to be certified for integration into a medical device – has been made available to them for this purpose. Beyond this, the teams have received a training for the hardware and coaching from KUKA experts throughout the competition. At virtual.MEDICA from 16-19.11.2020, the finalists presented their concepts to an international audience of experts and to the Innovation Award jury.
The winner of the KUKA Innovation Award 2020, worth 20,000 euros, is Team HIFUSK from the Scuola Superiore Sant'Anna in Italy.
[ KUKA Innovation Award ]
Like everything else the in-person Cybathlon event was cancelled, but the competition itself took place, just a little more distributed than it would have been otherwise.
[ Cybathlon ]
Matternet, developer of the world's leading urban drone logistics platform, today announced the launch of operations at Labor Berlin Charité Vivantes in Germany. The program kicked-off November 17, 2020 with permanent operations expected to take flight next year, creating the first urban BVLOS [Beyond Visual Line of Sight] medical drone delivery network in the European Union. The drone network expects to significantly improve the timeliness and efficiency of Labor Berlin’s diagnostics services by providing an option to avoid roadway delays, which will improve patient experience with potentially life-saving benefits and lower costs.
Routine BVLOS over an urban area? Impressive.
[ Matternet ]
Robots playing diabolo!
Thanks Thilo!
[ OMRON Sinic X]
Anki's tech has been repackaged into this robot that serves butter:
[ Butter Robot ]
Berkshire Grey just announced our Picking With Purpose Program in which we’ve partnered our robotic automation solutions with food rescue organizations City Harvest and The Greater Boston Food Bank to pick, pack, and distribute food to families in need in time for Thanksgiving. Berkshire Grey donated about 40,000 pounds of food, used one of our robotic automation systems to pick and pack that food into meal boxes for families in need, and our team members volunteered to run the system. City Harvest and The Greater Boston Food Bank are distributing the 4,000 meal boxes we produced. This is just the beginning. We are building a sponsorship program to make Picking With Purpose an ongoing initiative.
[ Berkshire Grey ]
Thanks Peter!
We posted a video previously of Cassie learning to skip, but here's a much more detailed look (accompanying an ICRA submission) that includes some very impressive stair descending.
[ DRL ]
From garage inventors to university students and entrepreneurs, NASA is looking for ideas on how to excavate the Moon’s icy regolith, or dirt, and deliver it to a hypothetical processing plant at the lunar South Pole. The NASA Break the Ice Lunar Challenge, a NASA Centennial Challenge, is now open for registration. The competition will take place over two phases and will reward new ideas and approaches for a system architecture capable of excavating and moving icy regolith and water on the lunar surface.
[ NASA ]
Adaptation to various scene configurations and object properties, stability and dexterity in robotic grasping manipulation is far from explored. This work presents an origami-based shape morphing fingertip design to actively tackle the grasping stability and dexterity problems. The proposed fingertip utilizes origami as its skeleton providing degrees of freedom at desired positions and motor-driven four-bar-linkages as its transmission components to achieve a compact size of the fingertip.
[ Paper ]
“If Roboy crashes… you die.”
[ Roboy ]
Traditionally lunar landers, as well as other large space exploration vehicles, are powered by solar arrays or small nuclear reactors. Rovers and small robots, however, are not big enough to carry their own dedicated power supplies and must be tethered to their larger counterparts via electrical cables. Tethering severely restricts mobility, and cables are prone to failure due to lunar dust (regolith) interfering with electrical contact points. Additionally, as robots become smaller and more complex, they are fitted with additional sensors that require more power, further exacerbating the problem. Lastly, solar arrays are not viable for charging during the lunar night. WiBotic is developing rapid charging systems and energy monitoring base stations for lunar robots, including the CubeRover – a shoebox-sized robot designed by Astrobotic – that will operate autonomously and charge wirelessly on the Moon.
[ WiBotic ]
Watching pick and place robots is my therapy.
[ Soft Robotics ]
It's really, really hard to beat liquid fuel for energy storage, as Quaternium demonstrates with their hybrid drone.
[ Quaternium ]
Thanks Gregorio!
State-of-the-art quadrotor simulators have a rigid and highly-specialized structure: either are they really fast, physically accurate, or photo-realistic. In this work, we propose a novel quadrotor simulator: Flightmare.
[ Flightmare ]
Drones that chuck fire-fighting balls into burning buildings, sure!
[ LARICS ]
If you missed ROS World, that's okay, because all of the talks are now online. Here's the opening keynote from Vivian Chu and Diligent robotics, along with a couple fun lightning talks.
[ ROS World 2020 ]
This week's CMU RI Seminar is by Chelsea Finn from Stanford University, on Data Scalability for Robot Learning.
Recent progress in robot learning has demonstrated how robots can acquire complex manipulation skills from perceptual inputs through trial and error, particularly with the use of deep neural networks. Despite these successes, the generalization and versatility of robots across environment conditions, tasks, and objects remains a major challenge. And, unfortunately, our existing algorithms and training set-ups are not prepared to tackle such challenges, which demand large and diverse sets of tasks and experiences. In this talk, I will discuss two central challenges that pertain to data scalability: first, acquiring large datasets of diverse and useful interactions with the world, and second, developing algorithms that can learn from such datasets. Then, I will describe multiple approaches that we might take to rethink our algorithms and data pipelines to serve these goals. This will include algorithms that allow a real robot to explore its environment in a targeted manner with minimal supervision, approaches that can perform robot reinforcement learning with videos of human trial-and-error experience, and visual model-based RL approaches that are not bottlenecked by their capacity to model everything about the world.
[ CMU RI ] Continue reading
Posted in Human Robots